Novel Therapy for Type 2 Diabetes
(REGENT-1-US Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new procedure using the Endogenex Device to help regenerate the lining of the small intestine. It targets patients with type 2 Diabetes who are not well-controlled on their current medications. The goal is to improve how their bodies process sugar and manage blood sugar levels better.
Who Is on the Research Team?
Daniel DeMarco, MD
Principal Investigator
Baylor Scott & White
Are You a Good Fit for This Trial?
This trial is for adults aged 22-65 with type 2 diabetes, who have been unable to control their blood sugar levels despite taking 2-3 non-insulin medications. Participants should have a BMI of 24-40 and a stable weight, without any significant gastrointestinal or autoimmune diseases, no recent insulin use (except for gestational diabetes), and not be on certain other medications.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the Endogenex procedure for duodenal mucosal regeneration
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- The Endogenex Device
Find a Clinic Near You
Who Is Running the Clinical Trial?
Endogenex, Inc.
Lead Sponsor
DyaMX Inc.
Lead Sponsor